Pitt

Vitalchat’s Inpatient Telehealth Solutions Now Can Now Be Paired with Samsung TV Models for Healthcare Environments

Retrieved on: 
Thursday, October 12, 2023

With missions to define the hospital of the future, inpatient telehealth innovator Vitalchat announced today its partnership with Samsung Electronics Co., Ltd.

Key Points: 
  • With missions to define the hospital of the future, inpatient telehealth innovator Vitalchat announced today its partnership with Samsung Electronics Co., Ltd.
  • The Vitalchat app, which offers immediate access to the company’s patented telehealth solutions, can now be paired with Samsung’s healthcare displays to deliver a more informed, comfortable and personalized patient care ecosystem.
  • “Our telehealth technology is designed to meet the needs of modern healthcare environments today and tomorrow,” said Vitalchat CEO Alan Pitt, MD.
  • With Samsung healthcare TVs, hospitals can also be fully set up with the telehealth technology within minutes versus days, negating patient room downtime.

AMERICAST Provides PreCast Pads to Charge Stations

Retrieved on: 
Saturday, September 23, 2023

PALM BEACH, Fla., Sept. 23, 2023 /PRNewswire/ -- Americast is now manufacturing and distributing its PreCast pads to Electric Car Charge Stations throughout America. In 2016, Warren Buffett acclaimed Americast as the "Rolls Royce of Generator Pads". Buffett further touted Charles Pitt, CEO of Americast for his "Pride in workmanship" and the "elegance of Americast PreCast Pads". Pitt states that: "Generator manufacturers and electric car makers have achieved an elegant look, and we have matched this elegance with our Precast pads. We accomplish this through attention to detail including hand crafted and hand polished pads. We take pride not only in our pads but in our ability to ship the same day that they are ordered. For an added touch of elegance and marketing, we can emboss the Dealer's Logo into the pads."

Key Points: 
  • PALM BEACH, Fla., Sept. 23, 2023 /PRNewswire/ -- Americast is now manufacturing and distributing its PreCast pads to Electric Car Charge Stations throughout America.
  • In 2016, Warren Buffett acclaimed Americast as the " Rolls Royce of Generator Pads ".
  • Buffett further touted Charles Pitt, CEO of Americast for his "Pride in workmanship" and the " elegance of Americast PreCast Pads ".
  • Pitt states that: "Generator manufacturers and electric car makers have achieved an elegant look, and we have matched this elegance with our Precast pads.

Voice referendum: is the 'yes' or 'no' camp winning on social media, advertising spend and in the polls?

Retrieved on: 
Wednesday, August 30, 2023

The “yes” and “no” campaigns for a Voice to Parliament are about to be supercharged as both sides begin a six-week countdown to voting day.

Key Points: 
  • The “yes” and “no” campaigns for a Voice to Parliament are about to be supercharged as both sides begin a six-week countdown to voting day.
  • This includes the key messages that are getting the most public attention – in the news, social media, online ads and opinion polls.
  • To win, “yes” needs to get a majority of voters in a majority of states.

What’s happening in the news?

    • This week it is averaging 7,184 mentions, showing how attention to the debate is slowly building since the start of the year.
    • To date, public engagement through media and social media posts is more likely to be piqued by criticism of the Voice than support for it.

What’s trending on social media?

    • When we look at who and what is getting public attention on Facebook and X, it is most often conservative figures and politicians sharing Sky News reports critical of the Voice.
    • In the past three months, the top five items that have had the most interactions - tens of thousands of shares each and reaching more than 6 million viewers collectively - on X and Facebook, are:


    These snapshots are concerning because some stories contain misleading information such as Pitt linking the Voice to state laws. But they also show the power of negative stories to attract attention, and the reach of Rupert Murdoch’s Sky News TV stories beyond its paywall.

What’s happening in online advertising?

    • About 14% of ad spending is reserved for elsewhere, namely South Australia ($73,528) and Tasmania ($26,739).
    • However, Yes23’s core messages are more disparate than the “no” ads paid for by Advance Australia for the “Fair Australia” campaign.
    • The “no” ad spend focuses on its stronghold states in Queensland ($33,652) and Western Australia ($27,234), and the possible flip-state South Australia ($16,6712).

How are the polls looking?

    • In looking at the key messages, the ad spend, and the polls, we can provide a snapshot of the state of the two campaigns so far.
    • As with any voting campaign, much can change as public attention sharpens as polling day looms.
    • He is an affiliate of the International Panel on the Information Environment (IPIE), and member of the Electoral Integrity Project‘s International Advisory Board.

Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh

Retrieved on: 
Tuesday, July 18, 2023

AUSTIN, Texas, July 18, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Pittsburgh (Pitt), granting Genprex a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to a gene therapy for both Type 1 and Type 2 diabetes using the genes of the Pdx1 and MafA transcription factors controlled by a MafB promoter. 

Key Points: 
  • "We are continuing to build a fortress of protection and a powerful intellectual property portfolio for our diabetes gene therapy program.
  • The addition of this license to MafB promoter technology expands and strengthens the potential for this novel, gene therapy to treat Type 1 and Type 2 diabetes," said Rodney Varner, Chairman, President and Chief Executive Officer at Genprex.
  • "In licensing this latest exclusive technology, which joins several others that provide us with multiple diabetes gene therapy combinations, we have valuable rights over what we believe are the most innovative, emerging diabetes gene therapies."
  • Earlier this year, the Company's research collaborators at the University of Pittsburgh presented preclinical data in a Non-Human Primate (NHP) model of Type 1 diabetes highlighting the therapeutic potential of GPX-002.

The Institute of Internal Auditors Names Sally-Anne Pitt as New Global Board Chair

Retrieved on: 
Wednesday, July 12, 2023

AMSTERDAM, July 12, 2023 /PRNewswire/ -- The Institute of Internal Auditors (IIA) - the internal audit profession's leader in standards, certifications, education, research, and technical guidance worldwide – today announced that Sally-Anne Pitt, CIA, CGAP will serve as the new Chair of the Global Board for 2023-2024 .

Key Points: 
  • AMSTERDAM, July 12, 2023 /PRNewswire/ -- The Institute of Internal Auditors (IIA) - the internal audit profession's leader in standards, certifications, education, research, and technical guidance worldwide – today announced that Sally-Anne Pitt, CIA, CGAP will serve as the new Chair of the Global Board for 2023-2024 .
  • Pitt joins the ranks of dedicated internal audit professionals from around the world who have served as The IIA's volunteer leader.
  • A Certified Internal Auditor (CIA) and Certified Government Audit Professional (CGAP) from Melbourne, Australia, Pitt is recognized globally for her expertise and leadership in internal audit.
  • She has more than a decade of volunteer experience with The IIA, most recently serving as Senior Vice Chair of the Global Board.

Costner builds a Field of Dreams - Pitt builds a Field of Power

Retrieved on: 
Monday, May 22, 2023

PALM BEACH, Fla., May 21, 2023 /PRNewswire/ -- FIELD OF POWER

Key Points: 
  • Buffett further touted Charles Pitt, CEO of Americast for his marketing success and the elegance of the Generator Pads.
  • "Generator manufacturers have achieved an elegant look," says Pitt, "and we have matched this elegance with our Generator pads.
  • We take special pride not only in our pads but in our ability to ship the same day that they are ordered.
  • Pitt continues his involvement in the arts: he recently signed with Hollywood Agent, Melissa Prophet who manages Joe Pesci after the release of Pitt Stars in Shakespeare & O'Neill .

First Mining Announces First Quarter 2023 Financial Results and Operating Highlights

Retrieved on: 
Monday, May 15, 2023

VANCOUVER, BC, May 15, 2023 /PRNewswire/ - First Mining Gold Corp. ("First Mining" or the "Company") (TSX: FF) (OTCQX: FFMGF) (FRANKFURT: FMG) reports its first quarter 2023 results for the quarter ended March 31, 2023.

Key Points: 
  • VANCOUVER, BC, May 15, 2023 /PRNewswire/ - First Mining Gold Corp. ("First Mining" or the "Company") (TSX: FF) (OTCQX: FFMGF) (FRANKFURT: FMG) reports its first quarter 2023 results for the quarter ended March 31, 2023.
  • The financial statements and management's discussion and analysis ("MD&A") are available on First Mining's website at www.firstmininggold.com/investors/reports-filings/financials/ and have been posted under the Company's profile on SEDAR at www.sedar.com and EDGAR at www.sec.gov .
  • "This has been an active quarter for First Mining for exploration activities at Springpole and Duparquet," stated Dan Wilton, CEO of First Mining.
  • "During Q1 2023, we embarked on our first district scale exploration program in the Birch-Uchi Greenstone Belt near our Springpole Gold Project and began preparations for an exploration program at our Duparquet Gold Project.

Pitt Stars in Shakespeare & O'Neill

Retrieved on: 
Monday, April 17, 2023

LOS ANGELES, April 17, 2023 /PRNewswire/ -- Talent Manager, Melissa Prophet is excited about her new talent: Charles Pitt. "I have never seen such a versatile actor who is so real and entertaining in a range from Shakespeare to O'Neill. He projects a dynamism that holds your attention; you can't take your eyes off him... you never see him coming in the spontaneity of his delivery. He's full of suprises."

Key Points: 
  • LOS ANGELES, April 17, 2023 /PRNewswire/ -- Talent Manager, Melissa Prophet is excited about her new talent: Charles Pitt .
  • "I have never seen such a versatile actor who is so real and entertaining in a range from Shakespeare to O'Neill.
  • He projects a dynamism that holds your attention; you can't take your eyes off him... you never see him coming in the spontaneity of his delivery.
  • Pitt's recent piece, "To be or not to fxcking be" combines both Shakespeare and O'Neill.

Sopheon CEO Honored as Distinguished Alumnus by University of Pittsburgh

Retrieved on: 
Tuesday, March 7, 2023

PITTSBURGH, March 07, 2023 (GLOBE NEWSWIRE) -- Sopheon , the InnovationOps software company, announced that CEO Greg Coticchia has been honored by the University of Pittsburgh’s Swanson School of Engineering.

Key Points: 
  • PITTSBURGH, March 07, 2023 (GLOBE NEWSWIRE) -- Sopheon , the InnovationOps software company, announced that CEO Greg Coticchia has been honored by the University of Pittsburgh’s Swanson School of Engineering.
  • Since earning his Bachelor of Science in Industrial Engineering and his MBA from the University of Pittsburgh, Coticchia has been a prominent figure in the Pittsburgh business community.
  • Coticchia was also named a Distinguished Alumni of the University of Pittsburgh Katz School of Business earlier in his career.
  • “I’m honored to receive this Distinguished Alumni Award from the institution that provided such a rock-solid foundation for my business career,” said Greg Coticchia, chief executive officer of Sopheon.

Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes at 16th Annual International Conference on Advanced Technologies & Treatment for Diabetes 2023

Retrieved on: 
Thursday, February 23, 2023

AUSTIN, Texas, Feb. 23, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that data highlighting the potential of Genprex's gene therapy for Type 1 diabetes is being presented by its research collaborators at the University of Pittsburgh (Pitt) at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) taking place February 22-25, 2023 in Berlin, Germany. 

Key Points: 
  • The complete presentation will be available on the Company's website here following the close of Dr. Kalsi's presentation.
  • They received a novel infusion process that used an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas.
  • "These results are compelling as they demonstrate the potential for this gene therapy to create newly formed beta-like cells that can produce insulin.
  • Importantly, it shows a positive data progression from our earlier mouse model data to these NHP data," noted Dr. Gittes.